Trial site
CABA
CABA, Buenos Aires F.D. C1424, ArgentinaNot linked to an institution yet
- 2running trials
- 8closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Completed8 trials
- Active, not recruiting2 trials
- Lead sponsor
- Sanofi9 trials
- Bioverativ, a Sanofi company1 trial
Closed trials
Completed
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
NCT05421598· Phase 2· Sanofi· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04751487· Phase 3· Sanofi· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
NCT04701983· Phase 3· Sanofi· Source
Completed
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
NCT04411641· Phase 3· Sanofi· Source
Completed
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
NCT04502862· Phase 4· Sanofi· Source
Completed
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
NCT04456673· Phase 3· Sanofi· Source
Completed
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
NCT04410991· Phase 3· Sanofi· Source
Completed
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)
NCT03560466· Phase 3· Sanofi· Source
Report an error